Zobrazeno 51 - 53
of 53
pro vyhledávání: ''
Autor:
N. Xiros, A. Karabelis, V. Kostopoulou, A. Gaglia, C. Valavanis, Michail Nikolaou, D.G. Pectasides, A Bobota, P. Arapantoni, N. Mylonakis
Publikováno v:
Journal of Clinical Oncology. 23:2094-2094
2094 Background: The aim of this prospective study was to evaluate mechanisms of resistance to trastuzumab in patients with MBC. Methods: Sixteen patients with Her2/neu overexpressing tumors (15 were 3+ by immunohistochemistry (IHC) and one 2+ by IHC
Publikováno v:
Journal of Clinical Oncology. 23:681-681
681 Background: Measuring HER2 is required for the selection of metastatic breast cancer (MBC) patients for trastuzumab therapy. Since the guideline was widely accepted that recommended initial tes...
Autor:
Silvana Martino, S. R. Dakhil, Peter A. Kaufman, Robert B. Jenkins, Wilma L. Lingle, Dylan V. Miller, E. A. Perez, Nancy E. Davidson
Publikováno v:
Journal of Clinical Oncology. 22:568-568
568 Background: Accurately and reliably identifying HER2/neu status is a critical priority in the treatment decision process. Current HER2 testing strategies include immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), but discre